Reduction of LDL-C, apo B & triglycerides; increase HDL-C in the management of hyperlipidemias including primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), hypertriglyceridemia (type IV); HoFH.
Do not give in patients w/ acute liver diseases or unexplained persistent raised serum-aminotransferase conc. Discontinue if marked increases in serum-aminotransferase or creatinine phosphokinase conc occur.
Sign Out
